Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation

Contemporary Clinical Trials

Volumn 29, Issue 2, 2008, Pages 157-164

  Fu, P ^a,b   van Heeckeren, W J ^b   Wadhwa, P D ^b,c   Bajor, D J ^b   Creger, R J ^b   Xu, Z ^a   Cooper, B W ^b   Laughlin, M J ^b   Gerson, S L ^b   Koc O N ^b   Lazarus, H M ^b  

^a Department of Epidemiology and Biostatistics ^*  (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Autologous stem cell transplantation; Non Hodgkin's lymphoma; Survival analysis; Time dependent effect; Tumor grade

Indexed keywords

CARMUSTINE; CISPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REFRACTORY PERIOD; RELAPSE; RISK FACTOR; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CISPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROPORTIONAL HAZARDS MODELS; STEM CELL TRANSPLANTATION; TIME; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 39049124134     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2007.07.005     Document Type: Article

References (30)

1. Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 (1993) 1002-1006
2. Czuczman M.S., Weaver R., et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with Rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22 (2004) 4711-4716
3. Fisher R.I. Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned and challenges remaining. J Natl Cancer Inst 93 (2001) 4-5
4. Milpied N., Deconinck E., et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350 (2004) 1287-1295
5. Vose J., Zhang M., Rowlings P., et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 19 (2001) 406-413
6. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
7. Lenz G., Dreyling M., Schiegnitz E., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104 (2004) 2667-2674
8. Schouten H.C., Qian W., Kvaloy S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP Trial. J Clin Oncol 21 (2003) 3918-3927
9. Deconinck E., Foussard C., Milpied N., et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105 (2005) 3817-3823
10. Lazarus H.M., Crilley P., Ciobanu N., et al. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. J Clin Oncol 10 (1992) 1682-1689
11. Wadhwa P.D., Fu P., Koc O.N., et al. High-dose carmustine, etoposide, cisplatin, autologous stem cell transplant with or without involved-field radiotherapy for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality. Biol Blood Marrow Transplant 11 (2005) 13-22
12. +Cell enrichment device. Br J Haematol 132 (2006) 42-55
13. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
14. Cox D.R. Regression models and life tables (with discussion). JR Stat Soc 34 (1972) 187-220
15. Zhang H., and Singer B. Recursive partitioning in the health sciences (1999), Springer-Verlag, New York
16. Schemper M. Cox analysis of survival data with non-proportional hazard functions. Statistician 41 (1992) 455-465
17. Therneau T.M., and Grambsch P.M. Modeling survival data: extending the cox model (2000), Springer-Verlag, New York
18. Klein J.P., and Moeschberger M.L. Survival analysis: techniques for censored and truncated data (1997), Springer-verlag, New York
19. Grambsch P.M., and Therneau T.M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81 (1994) 515-526
20. Zhang H. Detecting change points and monitoring biomedical data. Commun Stat Theory Methods 24 (1995) 1307-1324
21. Mathews D.E., and Farewell V.T. On testing for a constant hazard against a change-point alternative. Biometrics 38 (1982) 463-468
22. Liang K.Y., Self S.G., and Liu X. The Cox proportional model with change point: an epidemiologic application. Biometrics 46 (1990) 783-973
23. Luo X., Turnbull B.W., and Clark L.C. Likelihood ratio tests for a change-point with survival data. Biometrika 84 (1997) 555-565
24. Bradley E., and Tibshirani R.J. An Introduction to the Bootstrap (1993), Chapman and Hall
25. Mink S.A., and Armitage J.O. High-dose therapy in lymphomas: a review of the current status of allogenic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma. Oncologist 6 (2000) 247-256
26. Haioun C., et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a Groupe d' Etude des Lymphomes de l'Adulte Study. J Clin Oncol 18 (2000) 3025-3030
27. Schemper M. Cox analysis of survival data with non-proportional hazard functions. Statistician 41 (1992) 455-465
28. SAS version 9.1 (2002), SAS Institute Inc., Cary, NC, USA
29. Splus version 7.0 (2005), Insightful Cooperation, Seattle, USA
30. Loader C.R. Inference for a hazard rate change point. Biometrika 78 (1991) 749-757